Cellistic

Are you seeking a scalable, safe, and cost-effective solution to advance your cell therapy applications? All the ways lead to the Cellistic team in #Rome. Tarran Pierfelice, PhD, MBA, Gustavo Mahler and Peter Jaehn, Dr. will be in the Eternal City, participating in Alliance for Regenerative Medicine's #CGMed25. How can you integrate our Allo Chassis? immune-cloaked iPSC cell lines into your Cell Line Development program? What are the key features of our off-the-shelf Master Cell Bank? Wondering what IP strategies come with Cellistic's STAR-CRISPR? editing technology? Discover the answers to these questions and more about our integrated technologies for cell therapy development and manufacturing when you connect with our team in Rome. Book an appointment! ?? https://hubs.ly/Q03dr-b10

Enable broader therapeutic applications while significantly reducing costs and timelines associated with #CellLineDevelopment: this is what Cellistic’s immune-cloaked, off-the-shelf cell lines provide to therapeutic developers. Thanks to Cade Hildreth, B.A., M.S. - BioInformant for this insightful exchange that truly higlights how Allo Chassis? is transforming cell therapy treatments. ?? Want to know more? https://lnkd.in/ewUeEPCn #Cellistic #CellTherapy #OffTheShelf

Implementing GMP principles in the early stages of #CellLineDevelopment is crucial for ensuring the reliability and safety of therapeutic products through high-quality source materials. These essential principles not only enhance product consistency but also address key challenges in risk management and regulatory compliance. In their joint paper, Vincent Ernst, Quality Assurance Director, and Eric Mathieu, Senior Vice President of Operations at Cellistic, explore these advantages in detail and discuss best practices for implementation. ?? https://hubs.ly/Q039cbQ70 #Cellistic #CellTherapy #iPSCs #GMPPrinciples #GMP #cGMPG

In one month, the Cellistic team will be in Rome! ?? As a Gold Partner of Alliance for Regenerative Medicine' #CGMed25, we’re excited to contribute to this year’s program. Our CEO, Gustavo Mahler will take the stage to share scalable models and processes that optimize time and cost efficiency in cell line development and manufacturing, supported by data-driven insights. Much like Rome wasn’t built in a day, advancing cell therapies has its challenges—but with the right strategies, the journey becomes faster and more efficient. At Cellistic, we have the blueprint to accelerate this progress without compromising on quality. Our team is looking forward to connect with industry peers and showcase the solutions driving cell therapies forward in an era of growing demand. ??? https://hubs.ly/Q03bT5Fl0 See you in #Rome! Stefan Braam, Peter Jaehn, Dr., Tarran Pierfelice, PhD, MBA #Cellistic #CellTherapy #Allogeneic #iPSC

The efficiency of #AllogeneicCellTherapies heavily relies on precise gene editing, typically requiring an average of 6 to 8 different gene edits. This is where #automation plays a crucial role in #CellLineDevelopment processes, enabling the execution and validation of multiple gene modifications with high efficiency and reliability, overcoming the limitations imposed by manual genome editing. Stefan Braam, Stem Cell Expert and founder of Ncardia and Cellistic, and Suzanne Snellenberg doctor in advanced genome editing techniques and VP of Cell Line Development, review the key design criteria for a cell therapy cell line development platform and share the achievements of the CLD platform. Download the article via the link hereafter ?? https://hubs.ly/Q03b3xDH0 #Cellistic #CellTherapy #iPSC #CLD

Today marks an exciting moment for Cellistic with Tarran Pierfelice, PhD, MBA joining us as our new Chief Commercial Officer! As the demand for transformative cell therapies grows, Tarran will be at the forefront of driving our mission to make cell therapy accessible through state-of-the-art, off-the-shelf, and scalable iPSC solutions. With over a decade of experience in biopharma and a remarkable history of building strategic partnerships, she brings a wealth of expertise to propel Cellistic’s growth and redefine what’s possible in advanced therapies. Learn more about Tarran's experience in advancing therapies on Cellistic's blog ?? https://hubs.ly/Q03b3k_F0 and connect with us to pave a future where cutting-edge therapies are within everyone’s reach! #Cellistic #CellTherapy #Allogeneic #iPSCs #NewAppointment #CCO

Cellistic's Allo Chassis? immune-cloaked, off-the-shelf cell lines derived from CD34+ or CD4+ T-cell primary sources are designed to meet the demands of modern cell therapy. Here’s what sets them apart: ?? Proprietary STAR-CRISPR? Technology: Our cutting-edge technology allows for precise genetic modifications, enabling the creation of cell lines with enhanced therapeutic potential. ?? Automated Processes: Allo Chassis? integrates advanced automation to ensure consistency and efficiency in cell line development. This not only streamlines production but also reduces the risk of human error. ?? GMP Principles: Adhering to Good Manufacturing Practice (GMP) guidelines, we ensure that our cell lines are produced in a controlled and compliant environment, meeting the highest standards in the industry. ?? Quality Control: Rigorous quality control measures are implemented throughout the production process, guaranteeing the high safety and efficacy of our cell lines. With Allo Chassis?, you gain access to innovative, reliable iPSC cell lines that are tailored to enhance your research and development efforts. Interested in discovering how Allo Chassis? can transform your cell therapy development? Let’s chat and explore the possibilities!

??This is your reminder to book your Eurostar ticket or a flight to Heathrow. Peter Jaehn, Dr. will be in #London on March 18 and 19 for Advanced Therapies 2025! Questions about Cellistic's ready-to-use, immune-cloaked Allo Chassis? cell lines? Interested in how our iPSC-based allogeneic Cell Line Development and manufacturing technologies facilitate cost-effective development at scale? Connect with Peter! https://hubs.ly/Q038Ks610 #Cellistic #CellTherapy #Allogeneic #iPSCs #AdTherapies #AdvancedTherapies

?? How can companies balance innovation, exclusivity, and freedom to operate in a competitive landscape? ?? Which strategies help therapeutic developers secure a strong IP position while advancing gene-edited cell therapies? ?? What are the recent trends in CRISPR patenting and licensing complexities? A well-defined IP framework is essential for the development and commercialization of cell therapies. This is one of the pillars of Cellistic as a fully integrated platform for development and manufacturing of iPSC-based allogeneic therapies, we provide pre-defined licensing terms and a strong IP position through commercialization, integrating proprietary STAR-CRISPR? editing technology. ?? Gain Sergei Kurkin's expert insights into patent strategies, licensing challenges and options, and key considerations for gene editing in cell therapies: https://hubs.ly/Q0367V0j0 #Cellistic #CellTherapy #GeneEditing #IPStrategy #CRISPR

Cellistic's Allo Chassis? provides immune-cloaked iPSC cell lines derived from primary CD34 or CD4+ T-cells, available for immediate use. These reprogrammed and edited cell lines are backed by Cellistic's intellectual property and extensively documented in accordance with GMP principles. This offering not only saves valuable time and development costs but also ensures a compliant start to your cell therapy development. Curious how Allo Chassis? can accelerate your Cell Therapy Development? ?? Visit https://hubs.ly/Q0376Kld0 ?? Connect with Gustavo Mahler, Peter Jaehn, Dr., Holly Gills or Stefan Braam! #Cellistic #iPSCs #CellTherapy #OffTheShelfCellLines